Exelixis (EXEL): A Strong Momentum Stock with High Growth Potential for Investors Portfolios
Investing in the stock market can be a daunting task, especially for those who are new to the game. However, with the help of Zacks Style Scores, you can make informed decisions and narrow down your options to the best stocks for your portfolio. In this article, we'll take a closer look at Exelixis (EXEL), a biotech company that is making waves in the oncology field.
Exelixis (EXEL): A Biotech Powerhouse
Exelixis, Inc., based in Alameda, CA, is an oncology-focused biotechnology company that specializes in the discovery, development, and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise, and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs), and other biotherapeutics.
Momentum Score: A and VGM Score: A
For momentum investors, upward or downward trends in a stock's price or earnings outlook take precedence. That's why it's crucial to focus on the Momentum Style Score. EXEL boasts a Momentum Style Score of A and a VGM Score of A, which indicates that the stock is performing well and has strong potential for continued growth. Additionally, EXEL holds a Zacks Rank #2 (Buy) rating, which further solidifies its status as a top pick for investors.
Recent Price Action: Up 3.9% Over the Past Week
Shares of Exelixis have seen some interesting price action recently. The stock is up 3.9% over the past one week and up 2.3% over the past four weeks. In the last one-year period, EXEL has gained 94.3%. This upward trend is a clear indication that the stock is on the right track and has room for further growth.
Earnings Growth: Positive Outlook
Momentum investors don't just pay attention to price changes; positive earnings play a crucial role too. In the last 60 days, 10 analysts revised their earnings estimate upwards for fiscal 2025. The Zacks Consensus Estimate has increased from $2.31 to $2.61 per share, which is a significant jump. EXEL boasts an average earnings surprise of 48.6%, which means that the company has consistently exceeded analysts' expectations in terms of its earnings performance.
Strong Earnings Growth, Good Zacks Rank, and Top-Tier Scores
With strong earnings growth, a good Zacks Rank, and top-tier Momentum and VGM Style Scores, investors should think about adding EXEL to their portfolios. The company's focus on developing new drugs for difficult-to-treat cancers and its impressive track record of exceeding earnings expectations make it an attractive investment opportunity for both value and growth investors.
In Conclusion
If you're looking for a momentum stock with strong potential for growth, Exelixis (EXEL) is definitely worth considering. With its impressive track record of positive price action and earnings growth, as well as its top-tier Zacks Style Scores and rank, EXEL is a great addition to any investor's portfolio. Don't miss out on this opportunity to invest in a biotech powerhouse with a bright future ahead.
